Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79318.760.2889%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Dyne Therapeutics Inc

DYNNASDAQ
Trade with Public
Trade with Public
$24.28
-0.67-2.69%
At close: Sep 4, 5:00 PM EST
$24.28
N/A
After Hours: Sep 4, 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Dyne Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Dyne Therapeutics (DYN).

Price Target Range — 11 Quarters

Analyst Consensus — 18 Analysts

1S.Buy
15Buy
2Hold
Consensus RatingOutperform# Analysts18Avg. Consensus PT$40Upside to Avg. PT+65.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 31, 2026Morgan StanleyMichael UlzPT CutOverweight$47→$45
Jul 30, 2026RBC CapitalLuca IssiPT RaiseOutperform$30→$35
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35

RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and raises the price target from $30 to $35.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating.
Benzinga Newsdesk

PRO
TD Cowen Initiates Coverage On Dyne Therapeutics with Buy Rating

TD Cowen analyst Joseph Thome initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Buy rating.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $33

Evercore ISI Group analyst Gavin Clark-Gartner maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $34 to $33.
Benzinga Newsdesk

PRO
Bernstein Maintains Market Perform on Dyne Therapeutics, Raises Price Target to $24

Bernstein analyst William Pickering maintains Dyne Therapeutics (NASDAQ:DYN) with a Market Perform and raises the price target from $23 to $24.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved